Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Lymphoma 74Lymphoma, Large B-Cell, Diffuse 55Lymphoma, Non-Hodgkin 54Glioblastoma 41Lymphoma, Mantle-Cell 40Lymphoma, Follicular 37Hodgkin Disease 36Central Nervous System Neoplasms 32Gliosarcoma 29Brain Neoplasms 28Astrocytoma 28Lymphoma, Large-Cell, Immunoblastic 26Burkitt Lymphoma 25Multiple Myeloma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Glioma 20Oligodendroglioma 16Lymphoma, B-Cell, Marginal Zone 15Neoplasms, Plasma Cell 14Leukemia 13Recurrence 10Lymphoma, B-Cell 9Lymphoma, T-Cell 8Waldenstrom Macroglobulinemia 6Lymphoma, T-Cell, Cutaneous 6Leukemia, Myeloid, Acute 6Ependymoma 6Lymphoma, T-Cell, Peripheral 5Lymphoma, Large-Cell, Anaplastic 5

Interventions

Metformin 2Leuprolide 2Collagenases 2Clomiphene 2tremelimumab 1durvalumab 1Temozolomide 1Streptozocin 1Spironolactone 1Specimen Handling 1Radiosurgery 1Radiation 1Propofol 1Prednisone 1Plasma Exchange 1Nivolumab 1Midazolam 1Mercaptopurine 1Melphalan 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Infliximab 1Immunoglobulins 1High-Throughput Nucleotide Sequencing 1Fentanyl 1FANG vaccine 1Cyclophosphamide 1Clomipramine 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Rare Diseases × Carmustine × Clear all
NCT00004688 2015-03-25

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

FDA Office of Orphan Products Development

Phase 2 Completed
35 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Genetic Diseases, Inborn, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡